Replies to post #383391 on Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

Company survival is at stake. if B v C fails then the IBD indication was a KEY remaining focus. If oral B is now in doubt then the company may not survive B v C failure.

Oh yeah sure- trial will go on B UC in 2022. As if. All bets are off.